Posts tagged BLA.
Blogs
5 minute read
On February 15, 2019, the U.S. Food and Drug Administration (“FDA”) finalized two guidance documents regarding regenerative medicine therapies (see FDA’s announcement here). This development comes nearly 14 months after FDA issued both guidance documents in draft form, which also coincided with FDA’s announcement of a new comprehensive regenerative medicine policy framework intended to spur innovation and efficient access to new regenerative medicine products.
FDA Commissioner Scott Gottlieb remarked that the finalization of regenerative therapy guidance ...
Blog Editors
Recent Updates
- Legislative Push for FDA Preemptive Authority Over Dietary Supplement Regulation
- GUARD and GLOBE Pricing Models Could Test Manufacturer Rebates for Medicare Part B and D Drugs
- FDA’s Office of Dietary Supplement Programs Signals Key Enforcement and Policy Priorities for the Year Ahead
- OIG Issues Guidance, Request for Information on DTC Programs
- OIG Greenlights Cost-Sharing Waiver for Commercially Insured Patients